Drug intelligence / Profile preview

YXL

Development stage: Unknown
Lead developer: Chinese Academy of Medical Sciences
Modality: Small Molecules
Administration: Topical

Overview

YXL is a drug formulated as a topical ointment, currently under preliminary study for the treatment of psoriasis vulgaris. Clinical trials are investigating different concentrations (1% and 5%) of YXL ointment. The specific mechanism of action and molecular target of YXL are not disclosed in the provided information. The development of YXL is being conducted by the Clinical and Translational Medicine Research Project of Chinese Academy of Medical Sciences and the Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College.

Beyond the preview

Go deeper on YXL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YXL.

Explore the full profile